Blood cancers

Immunotherapy for multiple myeloma gets TGA tick

The CD38-directed monoclonal antibody daratumumab (Darzalex) has been listed by the TGA for the treatment of patients with refractory or relapsed multiple myeloma. The immunotherapy is the first in its class to receive a listing in Australia. It has been approved by the TGA for use: in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, ...

Already a member?

Login to keep reading.

© 2021 the limbic